tradingkey.logo

Arcellx soars after Gilead to acquire co for $7.8 billion

ReutersFeb 23, 2026 11:11 AM

Shares of cancer therapy developer Arcellx ACLX.O rise 77.5% to $113.78 premarket

Gilead Sciences GILD.O says it will buy ACLX for an implied equity value of $7.8 billion

The implied equity value includes $115 per share in cash at closing and one contingent value right of $5 per share

Up to last close, ACLX stock had fallen 1.7% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI